Brief: SK Bio, GSK Start Late-Stage COVID-19 Vaccine Trial

SK Bioscience Co

31/08/2021 07:19

Aug 31 (Reuters) - GlaxoSmithKline PLC  GSK.L :
    * GLAXOSMITHKLINE PLC  - SK BIO & GSK START PH3 COVID-19
VACCINE
TRIAL
    * GSK - ADVANCE TO PHASE 3 FOLLOWS POSITIVE INTERIM PHASE
1/2
IMMUNOGENICITY AND SAFETY DATA
    * GLAXOSMITHKLINE PLC  - SK BIO & GSK START PH3 COVID-19
VACCINE
TRIAL
    * GSK - GLOBAL CLINICAL TRIAL WILL EVALUATE VACCINE
CANDIDATE
GBP510 AGAINST AZ/OXFORD COVID-19 VACCINE
    * GSK - AIM IS FOR GLOBAL SUPPLY THROUGH COVAX FACILITY IN
FIRST
HALF OF 2022, SUBJECT TO DATA AND REGULATORY REVIEW
    * GSK - AIM IS FOR GLOBAL SUPPLY THROUGH COVAX FACILITY IN
FIRST
HALF OF 2022
    * GSK - NO SAFETY CONCERNS HAVE BEEN IDENTIFIED TO DATE IN
THIS
ONGOING STUDY.
    * GSK - ALSO ASSESSING WHETHER AN INVESTIGATIONAL MONOCLONAL
ANTIBODY, OTILIMAB, CAN HELP SEVERELY ILL COVID-19 PATIENTS AGED
OVER 70
    * GSK - GSK IS ALSO EXPLORING POTENTIAL THERAPEUTIC OR
TREATMENT
OPTIONS FOR COVID-19 PATIENTS

Source text for Eikon:  ID:nRSe1086Ka 
Further company coverage:  GSK.L 

 ((Reuters.Briefs@thomsonreuters.com;))